工具变量
认知
荟萃分析
随机对照试验
计算机科学
医学
内科学
精神科
机器学习
出处
期刊:
[BMJ]
日期:2022-08-30
卷期号:: o2094-o2094
被引量:14
摘要
Bapineuzumab-1, Solanezumab-1, Solanezumab-2, and Gantenerumab.Data for the EMERGE and ENGAGE trials of Aducanumab were previously obtained from the only source available at the time, but cognitive data for these trials were subsequently updated on ClinicalTrials.govand are shown here.Data from a publication available at the time of original publication were replaced with data from ClinicalTrials.gov for Verubecestat-2. 2The updated results do not include data that are not currently publicly available (Lecanemab) or from trials that were not completed at the time of the original publication (Donanemab).Figure 1, figure 2, figure 3, and figure 4 show the updated results.These results do not substantively change the primary results in the original publication: the meta-analyzed estimate of the effect of amyloid reduction on cognitive change as measured with the mini-mental state examination across 40 arms of 14 trials is small and consistent with the null.
科研通智能强力驱动
Strongly Powered by AbleSci AI